Esco Aster
Singapore, SG
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
63.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
Quick Facts: Esco Aster
- Signal Score
- 63.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Singapore, SG
- Modalities
- Cell Therapy, Exosome
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy, Exosome
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Parent company: Esco Group
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Esco Group
SEC FilingsParent: Esco Group
Parent company: Esco Group
Financial assessment: 68.0/100
Capacity
58.0
1 CGT manufacturing site: Singapore, SG
Modalities: Cell Therapy, Exosome
Capacity assessment: 58.0/100
Sites: Singapore, SG
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press1 articles
1 CGT manufacturing site: Singapore, SG
Modalities: Cell Therapy, Exosome
Capacity assessment: 58.0/100
Recent News 1 articles
Lipid Nanoparticles (LNPs) CDMO Market Global Trends and Growth Outlook 2026 to 2035 - openPR.com
Lipid Nanoparticles (LNPs) CDMO Market Global Trends and Growth Outlook 2026 to 2035 openPR.com
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: